335 related articles for article (PubMed ID: 16935227)
1. Comparison of pattern visual-evoked potentials to perimetry in the detection of visual loss in children with optic pathway gliomas.
Kelly JP; Weiss AH
J AAPOS; 2006 Aug; 10(4):298-306. PubMed ID: 16935227
[TBL] [Abstract][Full Text] [Related]
2. Can screening for optic nerve gliomas in patients with neurofibromatosis type I be performed with visual-evoked potential testing?
Wolsey DH; Larson SA; Creel D; Hoffman R
J AAPOS; 2006 Aug; 10(4):307-11. PubMed ID: 16935228
[TBL] [Abstract][Full Text] [Related]
3. Screening and diagnosis of optic pathway gliomas in children with neurofibromatosis type 1 by using sweep visual evoked potentials.
Chang BC; Mirabella G; Yagev R; Banh M; Mezer E; Parkin PC; Westall CA; Buncic JR
Invest Ophthalmol Vis Sci; 2007 Jun; 48(6):2895-902. PubMed ID: 17525226
[TBL] [Abstract][Full Text] [Related]
4. Visual function assessed by visually evoked potentials in optic pathway low-grade gliomas with and without neurofibromatosis type 1.
Dotto PF; Berezovsky A; Cappellano AM; da Silva NS; Sacai PY; Silva FAB; Fernandes AG; Rocha DM; Salomão SR
Doc Ophthalmol; 2018 Jun; 136(3):177-189. PubMed ID: 29766345
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of VEP perimetry in normal subjects and glaucoma patients.
Bengtsson B
Acta Ophthalmol Scand; 2002 Dec; 80(6):620-6. PubMed ID: 12485283
[TBL] [Abstract][Full Text] [Related]
6. Visual loss in children with neurofibromatosis type 1 and optic pathway gliomas: relation to tumor location by magnetic resonance imaging.
Balcer LJ; Liu GT; Heller G; Bilaniuk L; Volpe NJ; Galetta SL; Molloy PT; Phillips PC; Janss AJ; Vaughn S; Maguire MG
Am J Ophthalmol; 2001 Apr; 131(4):442-5. PubMed ID: 11292406
[TBL] [Abstract][Full Text] [Related]
7. Clinical ability of pattern electroretinograms and visual evoked potentials in detecting visual dysfunction in ocular hypertension and glaucoma.
Parisi V; Miglior S; Manni G; Centofanti M; Bucci MG
Ophthalmology; 2006 Feb; 113(2):216-28. PubMed ID: 16406535
[TBL] [Abstract][Full Text] [Related]
8. [Long-term outcome of gliomas of the visual pathway in type 1 neurofibromatosis].
Schröder S; Baumann-Schröder U; Hazim W; Haase W; Mautner VF
Klin Monbl Augenheilkd; 1999 Dec; 215(6):349-54. PubMed ID: 10637799
[TBL] [Abstract][Full Text] [Related]
9. VEP testing and visual pathway gliomas: not quite ready for prime time.
Siatkowski RM
J AAPOS; 2006 Aug; 10(4):293-5. PubMed ID: 16935225
[No Abstract] [Full Text] [Related]
10. Subclinical visual involvement in multiple sclerosis: a study by MRI, VEPs, frequency-doubling perimetry, standard perimetry, and contrast sensitivity.
Sisto D; Trojano M; Vetrugno M; Trabucco T; Iliceto G; Sborgia C
Invest Ophthalmol Vis Sci; 2005 Apr; 46(4):1264-8. PubMed ID: 15790888
[TBL] [Abstract][Full Text] [Related]
11. A fast visual evoked potential method for functional assessment and follow-up of childhood optic gliomas.
Trisciuzzi MT; Riccardi R; Piccardi M; Iarossi G; Buzzonetti L; Dickmann A; Colosimo C; Ruggiero A; Di Rocco C; Falsini B
Clin Neurophysiol; 2004 Jan; 115(1):217-26. PubMed ID: 14706491
[TBL] [Abstract][Full Text] [Related]
12. Amiodarone and optic neuropathy.
Domingues MF; Barros H; Falcão-Reis FM
Acta Ophthalmol Scand; 2004 Jun; 82(3 Pt 1):277-82. PubMed ID: 15115448
[TBL] [Abstract][Full Text] [Related]
13. Longitudinal measures of visual function, tumor volume, and prediction of visual outcomes after treatment of optic pathway gliomas.
Kelly JP; Leary S; Khanna P; Weiss AH
Ophthalmology; 2012 Jun; 119(6):1231-7. PubMed ID: 22364864
[TBL] [Abstract][Full Text] [Related]
14. Objective VEP perimetry in glaucoma: asymmetry analysis to identify early deficits.
Graham SL; Klistorner AI; Grigg JR; Billson FA
J Glaucoma; 2000 Feb; 9(1):10-9. PubMed ID: 10708226
[TBL] [Abstract][Full Text] [Related]
15. The role of visual electrodiagnostics in management of children with neurofibromatosis type 1.
Tekavčič Pompe M; Pečarič Meglič N; Šuštar Habjan M
Doc Ophthalmol; 2023 Apr; 146(2):121-136. PubMed ID: 36652041
[TBL] [Abstract][Full Text] [Related]
16. Central and peripheral steady-state visual evoked potentials in children with optic pathway gliomas.
Rassi SZ; Ospina LH; Bochereau A; Samson Y; Perreault S; Saint-Amour D
Doc Ophthalmol; 2019 Oct; 139(2):137-149. PubMed ID: 31243619
[TBL] [Abstract][Full Text] [Related]
17. [Visual information processing and the mechanism of vision. Clinical application].
Oguchi Y
Nippon Ganka Gakkai Zasshi; 1998 Dec; 102(12):850-75. PubMed ID: 10025116
[TBL] [Abstract][Full Text] [Related]
18. [Enlarged blind spot and reduced visual evoked potentials due to melanocytoma of the optic disc].
Heichel J; Slugocka-Jeziak K; Kühn E
Ophthalmologe; 2016 Dec; 113(12):1066-1069. PubMed ID: 27138117
[TBL] [Abstract][Full Text] [Related]
19. Comparing multifocal VEP and standard automated perimetry in high-risk ocular hypertension and early glaucoma.
Fortune B; Demirel S; Zhang X; Hood DC; Patterson E; Jamil A; Mansberger SL; Cioffi GA; Johnson CA
Invest Ophthalmol Vis Sci; 2007 Mar; 48(3):1173-80. PubMed ID: 17325161
[TBL] [Abstract][Full Text] [Related]
20. Risk of optic pathway glioma in children with neurofibromatosis type 1 and optic nerve tortuosity or nerve sheath thickening.
Levin MH; Armstrong GT; Broad JH; Zimmerman R; Bilaniuk LT; Feygin T; Li Y; Liu GT; Fisher MJ
Br J Ophthalmol; 2016 Apr; 100(4):510-4. PubMed ID: 26294105
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
